[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institute of Dermatology, Thailand\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":106},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100646604","poly-l-lactic-acid-plla-injection-for-neck-skin-laxity-a-pilot-study-100646604",false,"NCT07689344","Poly-L-lactic Acid (PLLA) Injection for Neck Skin Laxity: A Pilot Study","The Efficienctiveness of Poly-L-Lactic Acid, PLLA for the Treatment of Skin Laxity of the Neck: A Pilot Study","Inclusion Criteria:\n\n* Thai male or female participants aged 30-60 years\n* Individuals who wish to improve neck skin laxity\n* Presence of neck skin laxity grade 1-4 according to the Neck Skin Laxity Scale (NSL scale)\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* History of allergy or hypersensitivity to local anesthetics or components of collagen-stimulating substances\n* Active autoimmune disease requiring systemic treatment\n* History of cosmetic procedures in the neck area, including laser treatment, radiofrequency, or ultrasound-based devices within 6 months prior to treatment\n* History of dermal filler injection in the neck area\n* History of botulinum toxin injection in the neck area within 6 months prior to treatment",true,"ALL","30 Years","60 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"NA","Skin aging of the neck commonly leads to wrinkles and skin laxity due to the gradual loss of collagen and structural support in the skin. Although several treatments are available, effective non-surgical options for improving neck skin laxity remain limited. This pilot study aims to evaluate the effectiveness and safety of Poly-L-Lactic acid (PLLA) injections for improving neck skin laxity.",[28,29],"Skin Aging","Wrinkles",[31,32,33,34],"Poly-L-Lactic acid","PLLA","Neck rejuvenation","Skin laxity","NOT_YET_RECRUITING","2026-07-07",{"date":38,"type":39},"2026-07-08","ACTUAL",{"date":41,"type":22},"2026-07-01",{"date":43,"type":22},"2026-09-01",{"name":45,"class":46},"Institute of Dermatology, Thailand","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100646447","cholesterol-cream-vs-urea-cream-for-skin-barrier-and-quality-of-life-in-ichthyosis-100646447","NCT07689435","Cholesterol Cream vs Urea Cream for Skin Barrier and Quality of Life in Ichthyosis","A Comparative Study on the Efficacy of 10% Cholesterol Cream Versus 10% Urea Cream in Improving Skin Barrier Function and Quality of Life in Patients With Autosomal Recessive Congenital Ichthyosis","CURE-ARCI","Inclusion Criteria:\n\n1. Male or female patients aged 7 to 65 years\n2. Confirmed diagnosis of Autosomal Recessive Congenital Ichthyosis (ARCI), established by history, family\u002Fgenetic history, clinical presentation, and\u002For genetic testing\n3. Disease activity stable (not in an acute flare)\n4. Thai nationality\n5. Receiving care at the Institute of Dermatology\n6. Willing and able to provide informed consent (or, for participants under 18, assent with parental\u002Flegal guardian consent)\n\nExclusion Criteria:\n\n1. Presence of any other concurrent skin disease\n2. Known history of allergy to any component of the study creams\n3. Active skin infection (e.g., herpes zoster, viral, fungal, bacterial, or parasitic infection)\n4. History of any malignancy\n5. Pregnant (confirmed by positive urine pregnancy test), breastfeeding, or planning pregnancy during the study period","7 Years","65 Years",{"count":59,"type":22},24,[25],"This study looks at whether a cream containing 10% cholesterol works better than a cream containing 10% urea for people with autosomal recessive congenital ichthyosis (ARCI), a rare inherited skin condition that causes dry, thickened, scaly skin from birth.\n\nPeople with ARCI have a weakened skin barrier because their skin cannot properly produce or arrange the natural fats (lipids) needed to keep moisture in and irritants out. This leads to excessive water loss through the skin, dryness, itching, cracking, and a higher risk of skin infections. The current standard treatment is urea cream, which helps soften and remove scale but does not repair the underlying fat structure of the skin barrier. Cholesterol is one of the key natural fats that makes up a healthy skin barrier, so applying it directly to the skin may help rebuild that barrier more effectively than urea.\n\nIn this study, each participant will have one cream applied to one side of the body and the other cream applied to the matching area on the opposite side, so that each person acts as their own comparison. Researchers will measure how much water the skin loses (transepidermal water loss), skin hydration, and skin pH before and after treatment. They will also assess dryness and itching, take standardized clinical photographs, and ask participants to complete quality-of-life questionnaires (the Dermatology Life Quality Index, or its children's version, the Children's Dermatology Life Quality Index) as well as a satisfaction questionnaire for each cream.\n\nThe goal is to find out whether cholesterol cream restores the skin barrier better than urea cream, reduces dryness and itching more effectively, and leads to a better quality of life for people living with ARCI. The results may help guide more targeted skin care recommendations for this rare genetic condition.\n\nThis study is being conducted at the Institute of Dermatology, Bangkok, Thailand, and has been approved by the Institute's Ethics Committee.",[63,64,65],"Autosomal Recessive Congenital Ichthyosis","Skin Barrier Dysfunction","Ichthyosis Inherited",[63,67,68,69,70],"Cholesterol Cream","Urea Cream","Skin Barrier Function","Dermatology Life Quality Index",{"date":38,"type":39},{"date":73,"type":22},"2026-07-15",{"date":75,"type":22},"2027-06-30",{"name":45,"class":46},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100634162","veneze-peptide-factor-hair-serum-compared-with-topical-2-minoxidil-for-androgenetic-alopecia-100634162","NCT07536100","VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia","Effectiveness and Tolerability of VENEZE Peptide Factor Hair Serum for Pattern Hair Loss: A Randomized Double-blind Study","VENEZE-AGA","Inclusion Criteria:\n\n* Male or female participants aged ≥18 years.\n* Diagnosed with androgenetic alopecia (AGA): Norwood-Hamilton classification III-V in males or Ludwig classification I-II in females.\n* Able to read and write for completion of study questionnaires (e.g., Patient Global Assessment, Hair Growth Questionnaire).\n* Willing to comply with study procedures, including maintaining consistent hair color and hairstyle throughout the study.\n* Hair length in the non-balding area (vertex surrounding area) ≥2 cm at each visit.\n* Able to attend all scheduled visits during the 24-week study period.\n\nExclusion Criteria:\n\n* Presence of unstable or uncontrolled systemic diseases that may affect hair growth or loss within 6 months prior to screening (e.g., liver, renal, thyroid, cardiovascular, neurological diseases, diabetes, anemia).\n* History of malignancy within the past 5 years, except adequately treated basal cell carcinoma or squamous cell carcinoma.\n* Psychiatric disorders or other conditions that may affect participant safety or compliance.\n* Pregnant or breastfeeding women.\n\nHair and scalp-related exclusions:\n\n* Diffuse hair thinning involving the occipital area.\n* Scalp conditions or diseases affecting hair growth (e.g., tinea infection, non-AGA hair loss, psoriasis, uncontrolled seborrheic dermatitis).\n* History of hair transplantation at any time or hair extensions within 6 months prior to screening.\n* Use of cosmetic products for hair loss concealment within 2 weeks prior to screening.\n* Use of light\u002Flaser therapy on the scalp within 3 months prior to screening.\n* Use of supplements related to hair growth (e.g., zinc, biotin) within 3 months prior to screening.\n* Use of hair products containing active ingredients (e.g., caffeine, peptides) within 3 months prior to screening.\n* Hair procedures such as mesotherapy or stem cell injection within 3 months prior to screening.\n\nMedication-related exclusions:\n\n* Known hypersensitivity to study-related products or ingredients.\n* Use of dutasteride within 12 months prior to screening.\n* Use of systemic cytotoxic agents.\n* Use of systemic glucocorticoids within 3 months prior to screening (except inhaled or topical corticosteroids not applied to the scalp).\n* Use within 6 months prior to screening of:\n\n  * Minoxidil (topical or oral)\n  * Finasteride (topical or oral)\n  * Anti-androgenic drugs (e.g., spironolactone, cyproterone acetate, flutamide, bicalutamide)\n  * Prostaglandin analogs applied to the scalp\n  * Estrogen or progesterone topical preparations\n  * Tamoxifen\n  * Drugs associated with hypertrichosis (e.g., cyclosporine, phenytoin)\n  * Drugs associated with hair loss (e.g., valproic acid)\n* Participation in another clinical trial within 1 month prior to screening or during this study.","18 Years",{"count":87,"type":22},80,[25],"This study aims to evaluate the effectiveness and tolerability of a peptide-based hair serum compared with topical minoxidil in patients with androgenetic alopecia. Participants will be randomly assigned, in a double-blind manner, to receive either the peptide hair serum or topical minoxidil. The primary objective is to assess improvement in hair growth over the study period, including changes in hair density and hair thickness. Secondary outcomes will include safety and tolerability assessments. The findings of this study may provide evidence supporting an alternative treatment option for patients with androgenetic alopecia.",[91],"Androgenetic Alopecia (AGA)",[93,94,95],"Androgenetic alopecia","Peptide hair serum","Minoxidil","RECRUITING","2026-05-09",{"date":99,"type":39},"2026-05-13",{"date":101,"type":39},"2026-05-05",{"date":103,"type":22},"2026-11-30",{"name":45,"class":46},2,""]